Entrada Therapeutics Inc (TRDA) Stock Price, Quote & News

Company Profile

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 520 9158

Website: www.entradatx.com

Address:

One Design Center Place, Suite 17- 500, Boston, United States

VinWeezel Jun. 27 at 8:33 PM

$TRDA 400,000 shares traded ah and no price movement

0 · Reply

VinWeezel Jun. 25 at 4:46 PM

$TRDA https://www.tradingview.com/news/tradingview:da469c2620fe4:0-entrada-therapeutics-director-kim-peter-s-acquires-25-000-shares/ this was repoted again last week cause he filed wrong. He bought 25,000 two days in a row. But how did he pay 14 in may when price was 9? This guy is literally a genius. I’m adding.

1 · Reply

valueforme Jun. 17 at 1:19 AM

$TRDA Forgotten stock. Depending on what DYN has to say tomorrow, I might consider buying here

1 · Reply

VinWeezel May. 28 at 5:54 PM

$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-receives-authorization-in-the-european-union-to-oko6tip1t5oz.html

0 · Reply

VinWeezel May. 25 at 3:42 PM

$TRDA 16 this shortened week

0 · Reply

xrichsayzx88 May. 20 at 6:33 PM

$TRDA $10

0 · Reply

JarvisFlow May. 20 at 11:00 AM

HC Wainwright & Co. updates rating for Entrada Therapeutics ( $TRDA ) to Buy, target set at 20.

0 · Reply

VinWeezel May. 18 at 11:54 AM

$TRDA lets go to 16 this week 😬

0 · Reply

Uneducated_Trader May. 15 at 1:46 PM

$TRDA

0 · Reply

Armonica423 May. 10 at 5:20 PM

$TRDA Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

Jun 2, 2025, 4:30 PM EDT - 4 weeks ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2025, 7:00 AM EDT - 5 weeks ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 8, 2025, 7:00 AM EDT - 2 months ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Mar 24, 2025, 7:00 AM EDT - 3 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Feb 27, 2025, 7:00 AM EST - 4 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 4 months ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 19, 2025, 11:31 AM EST - 4 months ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 3, 2025, 7:00 AM EST - 5 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Jan 30, 2025, 4:05 PM EST - 5 months ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Dec 18, 2024, 7:00 AM EST - 7 months ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Oct 9, 2024, 7:00 AM EDT - 9 months ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Sep 24, 2024, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 17, 2024, 8:30 AM EDT - 10 months ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 6, 2024, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Jun 24, 2024, 7:15 AM EDT - 1 year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

Nov 22, 2023, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Sep 21, 2023, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 6:39 PM EDT - 2 years ago

Entrada Therapeutics: Early Stage But Interesting

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Apr 4, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Mar 29, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 6, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Dec 19, 2022, 4:30 PM EST - 2 years ago

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Dec 8, 2022, 8:24 AM EST - 2 years ago

Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 7:00 AM EST - 2 years ago

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

VRTX

Nov 7, 2022, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Aug 30, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Jul 19, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

Jul 6, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Jun 1, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

May 12, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2022 Financial Results

May 11, 2022, 9:30 AM EDT - 3 years ago

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

Apr 18, 2022, 9:48 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

ATER NEGG BEEM

Mar 15, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Feb 23, 2022, 8:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

VinWeezel Jun. 27 at 8:33 PM

$TRDA 400,000 shares traded ah and no price movement

0 · Reply

VinWeezel Jun. 25 at 4:46 PM

1 · Reply

valueforme Jun. 17 at 1:19 AM

$TRDA Forgotten stock. Depending on what DYN has to say tomorrow, I might consider buying here

1 · Reply

VinWeezel May. 28 at 5:54 PM

$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-receives-authorization-in-the-european-union-to-oko6tip1t5oz.html

0 · Reply

VinWeezel May. 25 at 3:42 PM

$TRDA 16 this shortened week

0 · Reply

xrichsayzx88 May. 20 at 6:33 PM

$TRDA $10

0 · Reply

JarvisFlow May. 20 at 11:00 AM

HC Wainwright & Co. updates rating for Entrada Therapeutics ( $TRDA ) to Buy, target set at 20.

0 · Reply

VinWeezel May. 18 at 11:54 AM

$TRDA lets go to 16 this week 😬

0 · Reply

Uneducated_Trader May. 15 at 1:46 PM

$TRDA

0 · Reply

Armonica423 May. 10 at 5:20 PM

$TRDA Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

Thestocktraderhubzee May. 8 at 11:17 AM

$TRDA Entrada Therapeutics Q1 EPS $(0.42) Beats $(0.76) Estimate, Sales $20.56M Beat $10.17M Estimate

0 · Reply

maizeblue22 Apr. 4 at 2:50 PM

$TRDA promising skeleton key-like tech, beat up by a red market. This is a steal at this SP

0 · Reply

Avocado_smash Apr. 1 at 4:21 PM

$TRDA 👇

0 · Reply

JarvisFlow Mar. 31 at 11:30 AM

HC Wainwright & Co. updates rating for Entrada Therapeutics ( $TRDA ) to Buy, target set at 20.

0 · Reply

Avocado_smash Mar. 30 at 4:14 PM

$TRDA PT 9.35 and lower low.

0 · Reply

TwongStocks Mar. 17 at 2:45 PM

$CAPR $TRDA Both companies will take part in a panel at the Roth Annual Conference today. <<Opportunities and Challenges in Duchenne Muscular Dystrophy>> 12:00pm ET/9:00am PT https://wsw.com/webcast/roth50/

1 · Reply

TulipmaniaJHH Mar. 12 at 6:29 AM

$TRDA jk my excel says no

0 · Reply

TulipmaniaJHH Mar. 12 at 6:27 AM

$TRDA deep value here

0 · Reply

PenkeTrading Mar. 8 at 12:33 AM

I found you a Morning Star Candle Pattern on the daily chart of Entrada Therapeutics Inc. $TRDA #Entrada #MorningStar #NASDAQ

0 · Reply

TwongStocks Mar. 3 at 3:03 PM

$CAPR Found some more specifics regarding their presentation at the Roth Conference on Mar 17. CAPR is taking part in a Panel, alongside $TRDA. "Opportunities and Challenges in Duchenne Muscular Dystrophy ( CAPR, TRDA)" Monday Mar 17 from 9:00-9:55am PT https://www.meetmax.com/sched/event_111373/conference_presentations.html Linda Marban (CEO of CAPR) and Nathan Dowden (President/COO of TRDA) will be on the panel.

0 · Reply

Thestocktraderhubzee Feb. 24 at 3:05 PM

$TRDA FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy

0 · Reply

JarvisFlow Feb. 24 at 1:26 PM

$TRDA (+5.1% pre) Entrada Therapeutics Receives FDA Approval for DMD Study

0 · Reply

Market Cap	274.40M
Revenue (ttm)	210.78M
Net Income (ttm)	65.63M
EPS (ttm)	N/A
PE Ratio	8.98
Forward PE	N/A
Profit Margin	31.14%
Debt to Equity Ratio	0.00

Volume	66,400
Avg Vol	137,236
Day's Range	N/A - N/A
Shares Out	37.95M
Stochastic %K	78%
Beta	-0.11
Analysts	Strong Sell
Price Target	$20.50